Enanta Pharmaceuticals (NASDAQ:ENTA) Earns Buy Rating from HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $18.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 267.35% from the stock’s previous close.

Several other research firms have also weighed in on ENTA. JMP Securities reissued a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Robert W. Baird dropped their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $4.90 on Tuesday. Enanta Pharmaceuticals has a one year low of $4.71 and a one year high of $17.80. The company has a 50-day moving average of $5.94 and a two-hundred day moving average of $9.68. The stock has a market cap of $104.52 million, a price-to-earnings ratio of -0.89 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Analysts anticipate that Enanta Pharmaceuticals will post -5.05 earnings per share for the current year.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 13.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Enanta Pharmaceuticals in the fourth quarter valued at approximately $26,000. US Bancorp DE lifted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the last quarter. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth $58,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Enanta Pharmaceuticals during the third quarter worth $122,000. Finally, AlphaQuest LLC lifted its position in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after buying an additional 3,137 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.